NASDAQ:ARDS Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ARDS Stock Alerts $0.06 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0750-Day Range$0.06▼$0.0852-Week Range$0.05▼$0.54Volume41,399 shsAverage Volume102,590 shsMarket Capitalization$3.09 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Aridis Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Read More ARDS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDS Stock News HeadlinesMarch 14, 2024 | uk.investing.comAridis Pharmaceuticals Inc (ARDS)February 10, 2024 | bbc.co.ukIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 15, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024November 3, 2023 | markets.businessinsider.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 1, 2023 | morningstar.comAridis Pharmaceuticals Inc ARDSOctober 22, 2023 | benzinga.comAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, PredictionsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. October 21, 2023 | msn.comHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy RecommendationOctober 20, 2023 | markets.businessinsider.comFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy RecommendationSeptember 15, 2023 | finance.yahoo.comARDS Sep 2023 2.500 callSeptember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVAugust 21, 2023 | investing.comAridis Pharma (ARDS) Earnings Dates & ReportsAugust 2, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2 Million OfferingJuly 18, 2023 | finance.yahoo.comWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?July 17, 2023 | finance.yahoo.comAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301July 13, 2023 | finance.yahoo.comAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301July 12, 2023 | finance.yahoo.comAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationJune 22, 2023 | marketwatch.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 20, 2023 | finance.yahoo.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 9, 2023 | finanznachrichten.deAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 8, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 1, 2023 | benzinga.comAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and ForecastMay 31, 2023 | finance.yahoo.comAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignMay 25, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QApril 26, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KSee More Headlines Receive ARDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/22/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDS CUSIPN/A CIK1614067 Webwww.aridispharma.com Phone(408) 385-1742Fax408-960-3822Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+3,000.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E Ratio0.92 P/E GrowthN/ANet Income$-30,370,000.00 Net Margins-5.11% Pretax Margin-5.11% Return on EquityN/A Return on Assets-20.47% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual Sales$3.09 million Price / Sales1.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.16) per share Price / Book-0.06Miscellaneous Outstanding Shares47,930,000Free Float45,293,000Market Cap$3.09 million OptionableNot Optionable Beta1.00 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Eric J. Patzer Ph.D. (Age 75)Founder & Executive Chairman Comp: $240kDr. Vu L. Truong Ph.D. (Age 60)Founder, CEO, Chief Scientific Officer & Director Comp: $631.65kDr. Hasan Jafri M.D. (Age 57)Chief Medical Officer Comp: $559.36kMs. Tamara S. Allen (Age 57)Vice President of Finance Mr. Jeffrey J. Fessler Esq. (Age 61)J.D., Acting General Counsel Key CompetitorsGeoVax LabsNASDAQ:GOVXPhaseBio PharmaceuticalsNASDAQ:PHASNexImmuneNASDAQ:NEXIAtrecaNASDAQ:BCEL60 Degrees PharmaceuticalsNASDAQ:SXTPView All Competitors ARDS Stock Analysis - Frequently Asked Questions Should I buy or sell Aridis Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDS shares. View ARDS analyst ratings or view top-rated stocks. What is Aridis Pharmaceuticals' stock price target for 2024? 1 brokers have issued 1 year price targets for Aridis Pharmaceuticals' stock. Their ARDS share price targets range from $2.00 to $2.00. On average, they predict the company's share price to reach $2.00 in the next year. This suggests a possible upside of 3,000.8% from the stock's current price. View analysts price targets for ARDS or view top-rated stocks among Wall Street analysts. How have ARDS shares performed in 2024? Aridis Pharmaceuticals' stock was trading at $0.0701 at the beginning of the year. Since then, ARDS stock has decreased by 8.0% and is now trading at $0.0645. View the best growth stocks for 2024 here. When is Aridis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ARDS earnings forecast. How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($0.51) by $1.43. The business earned $0.52 million during the quarter. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX). When did Aridis Pharmaceuticals IPO? Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARDS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
